The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The feasibility of alloSCT as consolidation therapy in R/R B-cell lymphoma exposed to bispecifics
Alberto Mussetti, MD, Institut Catala d’Oncologia Hospitalet, Barcelona, Spain, comments on a study investigating the feasibility of using allogeneic stem cell transplantation (alloSCT) as consolidation therapy in patients with relapsed/refractory (R/R) B-cell lymphomas exposed to bispecific antibodies. Dr Mussetti reports that the study found no increased concern about toxicity in patients receiving alloSCT after treatment with bispecifics, and that the efficacy results are promising. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this study, which has been a multicenter and international collaboration with other studies, led by the Spanish group of Transplant Cell Therapies, basically we observed that since bispecific antibodies are one of the possibly preferred therapeutic salvage strategies for patients relapsing after CAR T-cell therapy, the first thing that we would like to test if we are using such a strategy, if this could have an impact, especially about toxicity or on patients who will receive eventually a myeloallogenic transplantation...
In this study, which has been a multicenter and international collaboration with other studies, led by the Spanish group of Transplant Cell Therapies, basically we observed that since bispecific antibodies are one of the possibly preferred therapeutic salvage strategies for patients relapsing after CAR T-cell therapy, the first thing that we would like to test if we are using such a strategy, if this could have an impact, especially about toxicity or on patients who will receive eventually a myeloallogenic transplantation. And we observe that there is not an augmented concern about toxicity in this setting.
The other thing is that results are good. So for those patients which have been treated with bispecific antibodies who reached at least a partial response but the majority of them reached a complete response and followed by allogeneic transplant with any kind of donor and mostly with post-transplant cyclophosphamide GvHD prophylaxis, results are good and the cure rate is about 50 percent and we observed a plateau in survival curves after about one to two years. So hopefully these patients will be cured. And so the message is that yes, if you want to pursue an allogeneic transplantation after bispecifics, you can. Results are good and you don’t have to worry about increased toxicity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria for lectures: Takeda, BMS, Gilead, Sanofi; Honoraria for advisory board activities: Merck, Jazz Pharma; Participation in clinical trials (PI): Atara, Takeda; Research funding: Gilead.
